• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Merck's CEO Quits Trump's Council, President Tweets Back

    Bryan Mc Govern
    Aug. 14, 2017 02:20PM PST
    Pharmaceutical Investing
    Pharmaceutical Investing

    Following his resignation from President Donald Trump’s American Manufacturing Council, the CEO of Merck is under attack by tweets from the president.

    Following his resignation from President Donald Trump’s American Manufacturing Council on Monday morning (August 14), the CEO of Merck (NYSE:MRK) was the recipient of Trump’s tweets against his company.
    Kenneth C. Frazier used the company’s Twitter account to share his statement expressing a sense of duty to stand against the protestors in Charlottesville, Virginia over the weekend.
    “As CEO of Merck and as a matter of personal conscience, I feel a responsibility to take a stand against intolerance and extremism,” Frazier’s statement said. “Our country’s strength stems from its diversity and the contributions made by men and women of different faiths, races, sexual orientations and political beliefs.”

    pic.twitter.com/a1PNQZism5

    — Merck (@Merck) August 14, 2017

    Trump responds to Merck

    Frazier’s statement was released on August 14 at 8:00 a.m.EST; Trump’s response was made less than hour later.
    “Now that Ken Frazier of Merck Pharma has resigned from President’s Manufacturing Council, he will have more time to LOWER RIPOFF DRUG PRICES!”
    The president was criticized for not being able to immediately decry the protests that took place in Charlottesville from white supremacists groups, which ended in violence and three deaths.

    Now that Ken Frazier of Merck Pharma has resigned from President’s Manufacturing Council,he will have more time to LOWER RIPOFF DRUG PRICES!

    — Donald J. Trump (@realDonaldTrump) August 14, 2017


    It took Trump until Monday morning to call the protesters racists and condemn “criminals and thugs” utilizing KKK and Nazi symbols.
    Trump’s campaign included heavy promises of lowering the prices of drugs and has tweeted against pharma companies in the past. In February the president met with several top CEO’s in an effort to fulfill his campaign promise.
    The US Food and Drug Administration has taken steps to increase competition in the pharmaceutical space, including publishing a list of drugs that lack generic competition and discussing the possibility of taking a tougher stance on companies.

    Investor Takeaway

    Shares of the company didn’t experience a massive gain or decrease based on Trump’s reaction. At the close on Monday, Merck’s stock increased 0.37 percent and currently trades at $62.67. Over a year-to-date period the company has enjoyed a 6.52 percent increase.
    Don’t forget to follow @INN_LifeScience for real-time updates!
    Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

    pharmaceutical investingdonald trumptrumpfood and drug administration
    The Conversation (0)

    Go Deeper

    AI Powered
    Merck & Company

    Merck & Company

    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Latest News

    Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Invion Limited

    IVX:AU

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES